During the last three months, 13 analysts shared their evaluations of Apellis Pharmaceuticals APLS, revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 3 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 5 | 0 | 2 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $79.69, along with a high estimate of $100.00 and a low estimate of $46.00. Observing a downward trend, the current average is 7.24% lower than the prior average price target of $85.91.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds light on the perception of Apellis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Stringer | Needham | Maintains | Buy | $85.00 | $85.00 |
| Akash Tewari | Jefferies | Maintains | Buy | $80.00 | $80.00 |
| Colleen Kusy | Baird | Lowers | Outperform | $86.00 | $100.00 |
| Colleen Kusy | Baird | Maintains | Outperform | $100.00 | $100.00 |
| Salveen Richter | Goldman Sachs | Lowers | Buy | $77.00 | $90.00 |
| Colleen Kusy | Baird | Maintains | Outperform | $100.00 | $100.00 |
| Biren Amin | Piper Sandler | Announces | Neutral | $46.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $92.00 | $92.00 |
| Derek Archila | Wells Fargo | Lowers | Equal-Weight | $48.00 | $57.00 |
| Joseph Stringer | Needham | Maintains | Buy | $85.00 | $85.00 |
| Yigal Nochomovitz | Citigroup | Lowers | Buy | $60.00 | $67.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $92.00 | - |
| Eliana Merle | UBS | Lowers | Buy | $85.00 | $89.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Apellis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Apellis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Apellis Pharmaceuticals analyst ratings.
Delving into Apellis Pharmaceuticals's Background
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Key Indicators: Apellis Pharmaceuticals's Financial Health
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Apellis Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 284.26% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -38.55%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -28.8%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -8.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.41, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Significance of Analyst Ratings Explained
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
